MedTrace Logo

Reducing Acute Kidney Injury Occurence by Administering Angiotensin II

NCT05199493 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2023-03-24

No results posted yet for this study

Summary

The aim of this study is to evaluate whether adding angiotensin II to the standard of care is superior compared to the standard of care alone with respect to kidney damage (personalized approach) after cardiac surgery.

Conditions

  • Cardiac Surgery
  • Vasoplegia
  • Hyperreninemia

Interventions

DRUG

Angiotensin II

Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with the investigational drug.

DRUG

Control

Patients with Delta-renin \>= 3.7 micro-unit/mL are at high risk for AKI. Patients who have a high delta-renin and a postoperative hypotension requiring vasopressors ad will be randomized. After randomization patients will receive intravenous infusion with placebo

Sponsors & Collaborators

  • German Research Foundation

    collaborator OTHER

  • Universität Münster

    lead OTHER

Principal Investigators

  • Alexander Zarbock, MD · University Hospital Muenster, Dept. of Anesthesiology, Intensive Care Medicine and Pain Therapy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-27
Primary Completion
2022-12-19
Completion
2023-03-19

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05199493 on ClinicalTrials.gov